Amylyx to voluntarily withdraw ALS drug Relyvrio after Phase 3 fail, will lay off around 70%
04 Apr 2024
Phase 3
Amylyx announced Thursday morning that it will pull its ALS drug Relyvrio from the US and Canadian markets.
The decision comes as Amylyx will also lay off around 70% of its workforce in order to extend its cash runway to 2026, it said in a press release. Relyvrio will not be available for new patients as of today, but patients who are currently taking the therapy can continue to do so for free.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS and other neurodegenerative diseases,” co-CEOs Justin Klee and Joshua Cohen said in a
statement
.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.